Boceprevir (SCH 503034), a protease inhibitor, is under clinical development for the treatment of human hepatitis C virus infections. In human liver microsomes, formation of oxidative metabolites after incubations with [ 14 C]boceprevir was catalyzed by CYP3A4 and CYP3A5. In addition, the highest turnover was observed in recombinant CYP3A4 and CYP3A5. After a single radiolabeled dose to human, boceprevir was subjected to two distinct pathways, namely cytochrome P450-mediated oxidation and ketone reduction. Therefore, attempts were made to identify the enzymes responsible for the formation of carbonyl-reduced metabolites. Human liver S9 and cytosol converted ϳ28 and ϳ68% of boceprevir to M28, respectively, in the presence of an NADPHgenerating system. Screening of boceprevir with recombinant human aldo-keto reductases (AKRs) revealed that AKR1C2 and AKR1C3 exhibited catalytic activity with respect to the formation of 
Introduction
Hepatitis C virus (HCV) is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. Hepatitis C is the most common medical reason for liver transplantation worldwide and is a major cause of the increased incidence of hepatocellular cancer in the United States. The current paradigm for HCV treatment relies on pegylated interferon and ribavirin as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, sustained viral response rates remain suboptimal, with less than half of genotype 1-infected individuals going on to achieve sustained viral response. This response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents (Berman and Kwo, 2009) . Structural determination of key replication enzymes such as the HCV protease NS3/NS4 (nonstructural protein) has enabled the design and synthesis of new HCVspecific drugs. In particular, specifically targeted antiviral therapy against HCV heralds a new era in the treatment of patients with chronic hepatitis C. Specifically targeted antiviral therapy against HCV compounds blocks the action of the NS3/4A protease on the N-terminal domain of the HCV NS3 protein (Chen and Tan, 2005) . The NS3 protease is a serine protease essential for HCV polyprotein processing and therefore viral replication. NS3 forms a stable complex with the NS4A protein, which the protease requires as a cofactor, along with a structural zinc molecule, for optimal activity (Chen and Tan, 2005) .
Boceprevir (SCH 503034), a novel HCV NS3 serine protease inhibitor, is undergoing clinical evaluation for the treatment of HCV infections. Boceprevir binds reversibly to the NS3 protease active site and has potent activity in the replicon system alone (Malcolm et al., 2006) and in combination with interferon ␣-2b and ribavirin. Boceprevir is a mixture of two diastereomers, SCH 534128 (active) and SCH 534129 (inactive) , that differ in their stereochemical configuration at the third carbon atom (see Fig. 1A , ‫)ء‬ from the ketoamide end of the molecule. The drug substance is an amorphous powder with a diastereomer ratio of 1.15:1. In a recent rising single-dose safety and tolerance study, M28 and M31 were detected as the major metabolites of boceprevir in human plasma and urine (W. Tong, S. K. Chowdhury, and K. B. Alton, unpublished data). M28 and M31 are two carbonylreduced metabolites with a molecular mass that is 2 Da higher (Mϩ2) than that of boceprevir (see Fig. 1B ). These metabolites constitute two of the possible four stereoisomers arising from ketoreduction (Mϩ2) and were detected only at minor to trace levels after incubation with human liver microsomes. Boceprevir (see Fig. 1A ) is a mixture of two diastereoisomers that can be separated by high-performance liquid chromatography (HPLC). These diastereoisomers arise from the chiral center adjacent to the dicarbonyl moiety. Individually, these two isomers (SCH 534128 and SCH 534129) (see Fig. 1A ) were also incubated with human liver subcellular fractions and selected cytosolic enzymes. M31 coeluted with one of the diastereoisomers of boceprevir (SCH 534128) in the metabolite profiling method used for most of the experiments in this study. Therefore, formation of this metabolite could not be quantified in this study using radioprofile, and the kinetics of boceprevir was determined only for the formation of M28. However, the formation of M31 was confirmed by liquid chromatography (LC)-mass spectroscopy (MS).
Identification of the enzyme(s) responsible for the metabolism of a drug allows one to predict and/or explain interindividual differences that are due to differences in its metabolic clearance. Knowledge about cytochrome P450 (P450) and/or other enzymes(s) responsible for metabolism provides critical data for the design of drug-drug interaction studies in the clinic. The objective of this study was to identify the predominant in vitro biotransformation pathway(s) of boceprevir and enzyme(s) catalyzing those reactions.
Materials and Methods
Chemicals. Glucose 6-phosphate dehydrogenase, monosodium D-glucose 6-phosphate, NADP, magnesium chloride, Trizma base, ammonium acetate, allopurinol, flufenamic acid, menadione, ␣-naphthoflavone, omeprazole, orphenadrine, pargyline, quercetin, sulfaphenazole, tranylcypromine, quinidine, nonsteroidal anti-inflammatory drugs (NSAIDs), and all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Ketoconazole was purchased from Oxford Biomedical Research (Oxford, MI). HPLC-grade acetonitrile, acetic acid, and methanol (Optima) were obtained from Thermo Fisher Scientific (Waltham, MA). Distilled water was prepared using a Milli-Q water purification system from Millipore Corporation (Billerica, MA). Unlabeled boceprevir (SCH 503034) and two isomers, M28 and M31, were obtained from Merck (Kenilworth, NJ). Radiolabeled boceprevir ( 14 C, radiochemical purity Ͼ98%, specific activity 106 Ci/mg) was prepared by the Radiochemistry Group at Merck. Pooled human liver subcellular fractions were purchased from XenoTech, LLC (Lenexa, KS). Azamulin, P450 Supersomes, and CYP3A4 monoclonal antibodies (mAbs) were purchased from BD Biosciences (Woburn, MA).
Characterization of Metabolites. Metabolite characterization was performed using either LC with flow scintillation analysis (FSA) or LC coupled to an in-line mass spectrometer and FSA. For non-LC-MS-based analysis, a Waters Alliance HPLC system (Alliance model 2695; Waters, Milford, MA), equipped with model 996 Photodiode Array Detector (Waters), model 500TR flow scintillation analyzer (PerkinElmer Life and Analytical Sciences, Waltham, MA), and a 5-m Polaris C18-A, 250 ϫ 4.6-mm column (Varian, Inc., Lake Forrest, CA) were used. The column was maintained at 40°C for all HPLC experiments. The mobile phase consisted of 10 mM ammonium acetate adjusted to pH 7.0 with 1% ammonium hydroxide (A) and 100% methanol (B). The flow rate was maintained at 1 ml/min, and the metabolites were detected by UV at 254 nm. Gradient elution of metabolites was achieved using programmed linear changes in mobile-phase composition: 95% A/5% B (0 -5 min); 5-54% B (5-7 min); 54% B (7-26 min); 54 -65% B (26 -43 min); 65-95% B (43-46 min); 95% B (46 -49 min); and 95-5% B (49 -50 min), followed by equilibrium state for 10 min at 95% A.
All LC-MS and LC-tandem MS (MS/MS) experiments were performed on a Waters Alliance model 2695XE HPLC system coupled to a TSQ Quantum mass spectrometer (Thermo Fisher Scientific). HPLC mobile phases and separation conditions for all LC-MS/FSA and LC-MS/MS/FSA experiments were the same as described above. The HPLC column effluent was split so that ϳ16 to 24% of the flow was analyzed by the mass spectrometer, and the remaining fractions were diverted to the flow scintillation analyzer. This simultaneous detection of all drug-derived material by MS and FSA provided confirmation of the molecular mass and structure of all radioactive peaks in a single experiment.
The TSQ-Quantum mass spectrometer was equipped with an electrospray ionization source in positive ionization mode. Normal operating conditions were as follows: 3.4 to 5.0 V electrospray voltage, 350 -375°C heated capillary temperature, 37 to 49 sheath gas (N 2 ), 5 to 25 auxiliary gas (N 2 ), 1.5 mTorr collision gas (Ar), and 15 to 30 eV collision energy. All gas parameters are unitless softwarecontrolled settings related to gas flow or pressure. After LC-MS/FSA, the area of each detected radioactive peak in the flow scintillation analyzer was expressed as a percentage of the total chromatographic radioactivity.
Incubation with Pooled Human Liver Microsomes. Pooled human liver microsomes (1 nmol P450/ml) were incubated with 0.5, 1, 10, and 50 M [ 14 C]boceprevir for 120 min in the presence of an NADPH-generating system (0.5 mM NADP, 5 mM glucose 6-phosphate, and 1.5 units/ml glucose-6-phosphate dehydrogenase). Optimization of human liver microsomal incubation was performed with varying amounts (0.1-1 nmol P450/ml) of microsomes and over a range (5-120 min) of incubation periods. All incubation mixtures contained 3 mM magnesium chloride in 0.5 ml of 100 mM potassium phosphate buffer (pH 7.4). Before the addition of drug, the mixture was preincubated for 2 min at 37°C. Reactions were initiated by addition of drug, allowed to proceed for up to 120 min at 37°C, and then terminated by the addition of 0.5 ml of ice-cold acetonitrile with 1% acetic acid. The incubation mixture was vortexed and centrifuged (ϳ10,000g) at 4°C for 10 min, and supernatants were analyzed by HPLC/FSA. Boiled human liver microsomes and incubations without NADPH served as negative controls. Selected supernatants were analyzed by LC-MS/FSA after volume reduction to 100 to 200 l using a TurboVap at room temperature or a SpeedVac and reconstituting with 50 l of dimethyl sulfoxide containing 1% acetic acid.
Screening of 19 Human P450 Supersomes. The screening of 19 human P450 Supersomes (CYP1A1, CYP1A2, CYP2A6, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP4A11, CYP4F2, CYP4F12, CYP4F3A, and CYP4F3B) was conducted using a constant amount of cytochrome P450 (0.2 nmol/ml) and [
14 C]boceprevir (5 and 50 M) for 120 min. All incubations were performed in 0.5 ml of 100 mM potassium phosphate buffer (pH 7.4) (Ghosal et al., 2003) . For CYP2C9 and CYP2A6 Supersomes, incubations were performed in 100 mM Tris buffer (pH 7.4), according to the supplier's recommendation. Reactions were initiated and then terminated as described in the previous section. CYP3A4 and CYP3A5 Supersomes were also incubated for 30 and 60 min. Insect microsomes without cDNA of human P450 were used as control. Supernatants were also concentrated to ϳ100 l in SpeedVac and submitted for LC-MS/FSA analysis.
Inhibition with Chemical Inhibitors and CYP3A4-Inhibitory mAb. [ 14 C]Boceprevir metabolism was evaluated using selective chemical inhibitors of cytochrome P450 enzymes (ketoconazole and azamulin for CYP3A4, quinidine for CYP2D6, and sulfaphenazole for CYP2C9; tranylcypromine and dmd.aspetjournals.org Ͻ1%. Incubations were performed, and samples were analyzed by HPLC coupled with radioactivity detection. Human liver microsomal incubations without NADPH served as negative controls. bis(4-Nitrophenyl)-phosphate (BNPP), an inhibitor of carboxylesterase and/or amidase, was also used to explore the involvement of these enzymes.
Generation and Characterization of M؉2 Metabolite (M28). Incubation with human liver S9 fractions, cytosol, and mitochondria.
In a recent investigation, M28 and M31 were detected as major metabolites of boceprevir in human plasma and urine (W. Tong, S. K. Chowdhury, and K. B. Alton, unpublished data). Because M31 coeluted with SCH 534128, only M28 was quantified in this study. To explore the enzymology of this ketone-reduced metabolite, incubations with S9, cytosol, and mitochondria were conducted using a constant amount of protein (1.6 or 3.2 mg/ml) and [
14 C]boceprevir (20 M) for 120 min. S9 fractions were also incubated for 30 and 60 min. All incubations were performed as described earlier. Subcellular fractions without an NADPH-generating system were used as controls. For analysis by LC-MS/ FSA, selected supernatants were concentrated to ϳ100 l in a SpeedVac, reconstituted to ϳ150 to 300 l with dimethyl sulfoxide containing 1% acetic acid, and centrifuged before analysis. Selected samples were also analyzed by HPLC coupled with a flow scintillation analyzer and confirmed by LC-MS.
Inhibition with selective inhibitors of cytosolic enzymes. Inhibition of [ 14 C]boceprevir metabolism was evaluated using selective chemical inhibitors of cytosolic enzymes as summarized in Table 1 (Rosemond et al., 2004) . Human liver S9 and cytosol (1.6 mg protein/ml) were preincubated separately with various inhibitors for 15 min at room temperature, followed by the addition of buffer, cofactor, and substrate (20 M [ 14 C]boceprevir). All incubations were performed as described for human liver microsomes. Incubation volumes were 0.5 ml, and the final concentration of the organic solvents in the incubation system was Յ1% (v/v). Reactions were initiated by addition of substrate, allowed to proceed for 60 or 120 min at 37°C, and then terminated by the addition of 0.5 ml of ice-cold acetonitrile with 1% acetic acid. The incubation mixture was vortexed and centrifuged (ϳ10,000g) at 4°C for 10 min; supernatants were analyzed by HPLC with a flow scintillation analyzer.
Incubation of Boceprevir and Its Diastereoisomers (SCH 534128 and SCH 534129) with Recombinant Human Aldo-Keto Reductases. HEK293 cell lines expressing enzymes belonging to the hydroxysteroid dehydrogenase (HSD) family (AKR1C2, AKR1C3, AKR1C4, and control cells) were obtained from Merck to assess the involvement of these enzymes in the metabolism of boceprevir. Each cell line expressed a specific human recombinant enzyme. These are stably transfected cell lines expressing the following human enzymes: AKR1C2 (3␣-HSD type 3), AKR1C3 (17␤-HSD type 5 also known as 3␣-HSD type 2), and AKR1C4 (3␣-HSD type 1). In all cases, the enzyme activities of these cell lines were verified in-house through measurement of conversion of their known steroid substrates (Lin et al., 1997) .
The cells were propagated in tissue culture flasks, and the cell cultures were maintained at ϳ37°C in a humidified incubator in the presence of ϳ5% carbon dioxide. Cells were grown to confluency before harvesting the expressed enzymes. The cell lysate was centrifuged at ϳ9000g for ϳ30 min at ϳ4°C, and the resulting supernatant was collected as the S9.
Incubations of [ 14 C]boceprevir, 14 C SCH 534128, and 14 C SCH 534129 (all at 20 M) with S9 fractions from three recombinant human AKRs (2.5 mg protein/ml) were performed as described previously. The samples were analyzed by HPLC coupled with FSA and confirmed by LC-MS.
Inhibition of Boceprevir Metabolism in Pooled Human Liver Cytosol with Selective AKR Inhibitors. Inhibition of [
14 C]boceprevir metabolism was evaluated using known substrate and inhibitor of AKR enzymes: diazepam (Usami et al., 2002) , mefenamic acid, flufenamic acid (Steckelbroeck et al., 2004) , and ibuprofen (Yamamoto et al., 1998) . Inhibition studies were also conducted with ketoconazole and ritonavir (pre-and coincubation) to evaluate their inhibition potency. Human liver cytosol (1.6 mg protein/ml) was preincubated separately with various inhibitors for 15 min at room temperature, followed by the addition of buffer, cofactor, and substrate (20 M [
14 C]boceprevir). All incubations were performed as described for human liver microsomes with the exception of a 60-min incubation period instead of a 120-min incubation period, and the final concentration of the organic solvents in the incubation system was Յ1% (v/v).
Inhibition of M28 Formation from SCH 534128, SCH 534129 (with Human Liver Cytosol), and Boceprevir (with Recombinant AKRs). M28 formation from
14 C SCH 534128 and 14 C SCH 534129 was evaluated using selective chemical inhibitors of cytosolic enzymes, BNPP, diazepam, and NSAIDs (such as flufenamic acid and ibuprofen). Unlabeled SCH 534128 or SCH 534129 was incubated in the presence of BNPP as described previously. Human liver cytosol (1.6 mg protein/ml) was preincubated separately with various inhibitors for 15 min at room temperature followed by the addition of buffer, cofactor, and substrate (20 M 14 C SCH 534128 or 14 C SCH 534129). Reactions were initiated by addition of substrate, allowed to proceed for 30 or 60 min at 37°C, and then terminated by the addition of 0.5 ml of ice-cold acetonitrile with 1% acetic acid.
The effect of BNPP, flufenamic acid, diazepam, and ibuprofen on the formation of M28 from [
14 C]boceprevir with recombinant AKR1C2 and AKR1C3 was evaluated as described previously. AKR1C enzymes (2.5 mg protein/ml) were preincubated separately with various inhibitors for 15 min at room temperature followed by the addition of buffer, cofactor, and substrate (20 M [ 14 C]boceprevir). Reactions were initiated by addition of substrate, allowed to proceed for 120 min at 37°C, and then terminated by the addition of 0.5 ml of ice-cold acetonitrile with 1% acetic acid.
Analysis of Kinetic Data. Untransformed enzyme kinetic data were analyzed by a nonlinear regression data analysis program (GraFit 5.0.1; Erithacus Software Limited, Staines, UK), assuming Michaelis-Menten kinetics over the substrate range studied. (Table 2) . Human liver microsomes generated ϳ99 and 56% metabolites from boceprevir at 5 and 20 M, respectively ( Table 2) . Incubation of boceprevir (20 M) for various time periods (5-120 min) and P450 concentrations (0.1-1 nmol/ml) showed that the optimal time for the formation of oxidative metabolites was 30 min with a P450 concentration of 1 nmol/ml (data not shown). Human liver microsomes were incubated with various substrate concentrations (0.5-50 M), and a substrate concentration of 20 M was chosen for further experiments based on percent conversion and detection sensitivity. A representative radiochromatogram is provided in Fig. 2 . In the absence of the NADPH-generating system or with boiled microsomes, no metabolite formation was observed (data not shown). The recovery of radioactivity injected onto the HPLC column was ϳ100%; no radioactivity was observed in the protein-precipitated pellets after multiple washings.
Results

Optimization and Incubation with
Screening with Human P450 Supersomes. In vitro incubation of [ 14 C]boceprevir (5 and 20 M) with 17 different recombinant human P450 Supersomes (0.2 nmol/ml) showed that CYP3A4 and CYP3A5 exhibited the most activity, followed by markedly less substrate conversion with other cytochromes P450 such as CYP2D6 and CYP2C19 (Table 2 ). The formation of hydroxylated metabolites with recombinant CYP3A4 and CYP3A5 (Table 2 ) and disappearance of parent (Fig. 3 ) drug suggested involvement of these enzymes in the oxidative metabolism of boceprevir. CYP2J2 and CYP4F12 were also incubated with [ 14 C]boceprevir; however, no radioactive metabolites were detected (data not shown).
Metabolite Characterization. Selected samples of [ 14 C]boceprevir incubated with human liver microsomes and cDNA-expressed human P450 Supersomes (CYP3A4, CYP3A5, CYP2D6, CYP2C19, CYP1A2, CYP1A1, CYP2B6, and CYP4F3A) were analyzed by LC-MS/MS/FSA to verify and characterize the metabolites formed. The results are summarized in Table 2 , and structures of major metabolites are provided in Fig. 1B . CYP3A4 yielded ϳ100 and 43% metabolites from boceprevir at 5 and 20 M, respectively. CYP3A5 yielded ϳ97 and 42% metabolites from boceprevir at 5 and 20 M, respectively.
Inhibition with Selective P450 Inhibitors and Anti-CYP3A4 Antibody. The results of the chemical inhibition studies of [ 14 C]boceprevir (20 M) with selective chemical inhibitors of P450 showed that ketoconazole and azamulin (both are known CYP3A4/5 inhibitors) and CYP3A4-specific inhibitory mAb inhibited formation of major oxidative metabolites (M11, M14/M15/M16, M21, and M23) by 36 to 68% (Table 3 ). Other P450 inhibitors and an amidase inhibitor BNPP showed no inhibition (Table 3) . Ritonavir (a mechanism-based inhibitor of CYP3A) inhibited boceprevir metabolism (ϳ100%) at 2 M (Table 3) , however, to a much greater extent than ketoconazole and azamulin. Ritonavir also inhibited 100% after preincubation in the presence of NADPH. These inhibition studies suggested that CYP3A4 and CYP3A5 are primarily responsible for the metabolism of boceprevir to its oxidative metabolites.
Inhibitors of CYP3A4 (ketoconazole and ritonavir) and AKR (diflunisal) were compared for the inhibition of total oxidative metabolites. Ritonavir inhibited 100% even at 1 M, whereas ketoconazole inhibited 69.7% at 2 M (data not shown). Although diflunisal (200 M) was a known inhibitor of AKR, there was no inhibition of oxidative metabolites (CYP3A4 mediated), suggesting that diflunisal is not an inhibitor of CYP3A4 (data not shown).
Summary of P450 Identification. The results of P450 identification experiments suggest that CYP3A4 and CYP3A5 are involved in Ͼ95% loss of boceprevir at 5 M. Ketoconazole and azamulin (CYP3A4/5 inhibitors) inhibited metabolism of boceprevir, and CYP3A4-inhibitory mAb also inhibited metabolite formation at 2 g mAb/g protein. The results suggest that oxidative metabolites of boceprevir in human liver microsomes are primarily mediated by CYP3A4 and CYP3A5. 
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Generation and Characterization of M28.
To further explore the enzymology of M28 formation, incubations were performed with human liver subcellular fractions: S9, cytosol, and mitochondria in the presence and absence of an NADPH-generating system. The radiochromatographic profiles from human liver microsomes, S9, cytosol, and mitochondria are provided in Fig. 2 . The major metabolites formed were M28 and M31, primary circulating metabolites in human plasma. Extracted ion chromatograms and MS/MS spectra for boceprevir (m/z 520) and Mϩ2 metabolites (M28, M30, and M31; m/z 522) are shown in Fig. 4 .
In vitro incubations with human liver S9 and cytosol in the presence of an NADPH-generating system exhibited the most activity (ϳ28 and 68%, respectively) for the formation of M28; mitochondria produced far less (ϳ7% M28) (Fig. 2) . M31, a diastereoisomer of M28, was also formed (32-47%) from S9, cytosol, and mitochondria. However, because M31 and one of the parent drug diastereoisomers coelute, the extent of conversion of boceprevir to M31 may be biased high. No metabolite was detected in the absence of an NADPH-generating system (data not shown). The effect of various cofactors on the formation of M28 showed that the formation of this metabolite is NADPH dependent (data not shown). The NADPH-dependent formation of ketone-reduced metabolites such as M28 and M31 in S9 and cytosol suggested involvement of cytosolic AKR and/or carbonyl reductase (CBR) (short-chain dehydrogenase/reductase) (Rosemond et al., 2004) .
The effect of cofactors on the potential conversion of M28 back to its parent (boceprevir) was also explored. No significant conversion of M28 (20 M) to boceprevir was detected by LC-MS analysis when M28 (20 M) was incubated with human liver cytosol for 60 min at 37°C in the presence of 1 mM NADP or NADP ϩ NADPH (1:1) (data not shown).
Inhibition with Selective Inhibitors of Cytosolic Enzymes. The relative contributions of AKRs and CBR were determined using known chemical inhibitors of cytosolic enzymes (Fig. 5) . The results of the inhibition studies showed that flufenamic acid, mefenamic acid, and phenolphthalein (selective inhibitors of AKRs) inhibited formation of M28 by Ͼ76% in cytosol and S9, implicating the likely involvement of AKR(s) (Fig. 5) . BNPP, a known carboxylase/amidase inhibitor, inhibited M28 formation by 63.4 and 57.4% from cytosol and S9, respectively. However, amidase is not NADPH dependent, suggesting that its involvement, if any, is minimal. CBR and aldehyde oxidase inhibitors (menadione and quercetin) showed Ͻ30% inhibition, whereas monoamine oxidase (MAO)-A/MAO-B inhibitor (pargyline) and xanthine oxidase inhibitor (allopurinol) showed no inhibition. Because M31 coeluted with SCH 534128, a diastereoisomer of boceprevir, the inhibition of its formation with AKR and CBR inhibitors was not measured quantitatively. The cofactor dependence, subcellular location, and chemical inhibition data suggest that the AKR Incubation of Boceprevir, SCH 534128, and SCH 534129 with Human Liver Cytosol. The kinetics of M28 and M31 formation were determined using various concentrations (0.5-20 M) of boceprevir and human liver cytosol; the results are provided in Table 4 , and the representative chromatogram is provided in Fig. 6 . Samples were analyzed by an LC-MS/MS method using the ultrahigh separation capability of an ultraperformance liquid chromatography system. In this highly sensitive method, all four diastereoisomers of Mϩ2 metabolites (M28 and M31 are two major human metabolites) were separated and quantified. No other drug-related material was targeted in this method.
Incubation conditions of boceprevir, SCH 534128, and SCH 534129 were optimized with various concentrations of human liver cytosolic protein (0.8 -3.2 mg/ml) at various time periods (0, 30, 60, and 120 min). For boceprevir, optimal time was 60 min and protein concentration was 1.6 mg/ml. Kinetic parameter of boceprevir was determined with 0.5 to 100 M substrate concentration, and the results showed that K m values for M28 and M31 formation were 13.0 and 12.5 M, respectively (Table 4) . V max /K m data suggest that intrinsic clearance of M28 (2.2) and M31 (2.8) formation are similar, suggesting that they are equally involved in the in vitro biotransformation of (Table 4) . A substrate concentration of 20 M was chosen for further experiments with human liver microsomes considering the linearity and sensitivity of detection of M28 and M31.
For SCH 534128 and SCH 534129, optimal protein concentrations were 0.8 and 0.4 mg/ml and optimal time was 60 min. The kinetics of M28 and M31 formation were separately determined with various concentrations of SCH 534128 (2-100 M) and SCH 534129 (2-84 M) (two diastereoisomers of boceprevir) by using human liver cytosol. The results provided in Table 4 demonstrate that the in vitro intrinsic clearance value (V max /K m ) for M31 formation (30.9) from SCH 534129 is higher than that for M28 formation (10.2) from SCH 534128 ( Table 4 ), suggesting that in vivo clearance of SCH 534129 may be faster in humans.
Incubation of Boceprevir, SCH 534128, and SCH 534129 with Recombinant Human AKRs. Recombinant human AKR1C2, AKR1C3, and AKR1C4 enzymes were expressed in HEK293 cell lines [cell lines were obtained internally (Discovery Research; Merck, formerly Schering-Plough)]. S9 fractions were prepared as described under Materials and Methods and incubated with boceprevir. AKR1C1 was not available to explore its involvement. Boceprevir (20 M) incubation (120 min) with AKR1C2, AKR1C3, and AKR1C4 in the presence of NADPH showed that both AKR1C2 and AKR1C3 generated M28 and M31; however, AKR1C4 was not involved in the formation of either ketone-reduced metabolite. Furthermore, these data showed that AKR1C3 preferentially metabolized SCH 534128, the active isomer, and AKR1C2 preferentially metabolized SCH 534129, the inactive isomer (Fig. 7) . The results suggest that AKR1C2 and AKR1C3 are involved in the formation of M28 and M31 from boceprevir in human liver cytosol. 
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at ASPET Journals on June 22, 2017 dmd.aspetjournals.org AKR1C2 and AKR1C3 were incubated with boceprevir at various protein concentrations, and the optimal concentration for the formation of M28 was found to be 2.5 and 0.25 mg/ml, respectively. Kinetic studies were conducted at the optimal protein concentrations as stated earlier. Kinetic parameters of AKR1C2 and AKR1C3 for the metabolism of boceprevir are provided in Table 5 . Intrinsic clearance (V max /K m ) by M28 formation with AKR1C3 is higher than its formation by AKR1C2 (Table 5 ). These results suggest that AKR1C3 may be the preferred biotransformation pathway for the formation of M28 in human liver cytosol. In addition, Fig. 7 generates predominantly M28 with small amounts of M31, whereas AKR1C2 forms primarily M31 with small amounts of M28. Boceprevir consists of two diastereoisomers, SCH 534128 and SCH 534129. M28 is a major biotransformation product of SCH 534128, and M31 is that of SCH 534129 (Fig. 6 ). These data clearly indicate stereochemical specificity of AKR1C2 and AKR1C3 in the biotransformation of boceprevir.
Inhibition of Boceprevir Metabolism in Pooled Human Liver Cytosol with Selective AKR Inhibitors. The results of incubations of with human liver cytosol in the presence of various inhibitors are provided in Table 6 . Benzodiazepines and NSAIDs were used as inhibitors of AKRs (Usami et al., 2002; Desmond et al., 2003; Bauman et al., 2005) . At a concentration of Ն100 M, diazepam, ibuprofen, and diflunisal were shown to be potent inhibitors for the formation of M28 from human liver cytosol (ranged 70 -89%). IC 50 for ibuprofen and diflunisal for the formation of M28 was ϳ411.8 and 4.58 M (Table 6 ). Diflunisal is a potent inhibitor of M28 formation mediated by AKR, but it is not an inhibitor of oxidative metabolites formation catalyzed by CYP3A4 and CYP3A5. Ketoconazole and ritonavir did not have a significant effect on the formation of M28 from boceprevir.
The inhibition profile for metabolism of SCH 534128 and SCH 534129 (diastereomers of boceprevir) in human liver cytosol is shown in Fig. 8 . Flufenamic acid, diazepam, and ibuprofen inhibited AKRmediated M28 formation from SCH 534128 (80.5, 72.9, and 68.6%, respectively) and M31 formation from SCH 534129 (72, 78, and 63% inhibition, respectively) . BNPP, an amidase inhibitor, was found to inhibit M28 and M31 formation from both diastereoisomers by 65.6 and ϳ60%, respectively. In the literature, BNPP was not known as an inhibitor of AKRs.
Inhibition Studies with Recombinant AKR Enzymes. The effect of various inhibitors on the metabolism of boceprevir with recombinant AKR1C2 and AKR1C3 is illustrated in Fig. 9 . The results showed that flufenamic acid, diazepam, and ibuprofen are potent inhibitors of the AKR1C2-mediated formation of M28 (Ͼ89% inhibition). Flufenamic acid (93%) and ibuprofen (80%) are also potent inhibitors of AKR1C3, whereas diazepam only inhibits 55% (Fig. 9) . BNPP was found to inhibit both AKR1C2 and AKR1C3 by 82 and ϳ69%, respectively. In the literature, BNPP was not known as an inhibitor of AKR1C2 or AKR1C3. Because M31 coelutes with a parent, it was not possible to explore M31 inhibition potential.
Discussion
Clinically, following a single oral radiocarbon dose, ϳ79% of the dose was excreted in feces, and ϳ9.3% of the dose was cleared in urine (W. Tong, S. K. Chowdhury, and K. B. Alton, unpublished data). Approximately 50% of the dose was excreted in feces as oxidative metabolites including those derived from a combination of oxidation and reduction. The carbonyl reduction pathway involved ϳ22% of the dose excreted. However, metabolites produced via carbonyl reduction pathway (M28 and M31) predominate as the major circulating drug-derived metabolites. In contrast, only trace levels of M28 and M31 were detected following in vitro incubation with hepatic microsomes.
In vitro studies with recombinant cytochromes P450 showed that CYP3A4 and CYP3A5 are involved in Ͼ95% loss of boceprevir at 5, 20, and 50 M. Inhibition studies with human liver microsomes showed that CYP3A4 inhibitors (ketoconazole, azamulin, and ritonavir) and CYP3A4-inhibitory mAb inhibited the metabolism of boceprevir. The results show that oxidative metabolites of boceprevir in human liver microsomes are primarily mediated by CYP3A4 and CYP3A5. This observation is consistent with the metabolism and excretion data from a human radiolabeled Absorption, Metabolism and Excretion study (W. Tong, S. K. Chowdhury, and K. B. Alton, unpublished data) in that a significant component of clearance of boceprevir involved oxidative metabolism.
Human liver subcellular fractions (S9, cytosol, and mitochondria) and flavin-containing monooxygenases were screened for the formation of Mϩ2 metabolites. The results showed that cytosol and, to some extent S9, generated significant amounts of Mϩ2 metabolites (M28 and M31) but only in the presence of NADPH. Hence, the enzyme system responsible for generation of Mϩ2 metabolites in vitro was believed to be cytosolic and NADPH dependent. These data suggest that another major clearance pathway involves ketone reduction and is consistent with the radiocarbon excretion and metabolism data. To further characterize the metabolism of boceprevir, known inhibitors of cytosolic enzymes were used as follows: menadione for CBR and aldehyde oxidase; BNPP for amidase and carboxylesterase (Martin et al., 1997) ; pargyline for MAO-A and MAO-B; quercetin for CBR; allopurinol for xanthine oxidase, and flufenamic acid, mefenamic acid, and phenolphthalein for AKRs (Higaki et al., 2003; Rosemond et al., 2004; Jin and Penning, 2007) . Inhibition of Mϩ2 formation was Ͼ80% by flufenamic acid, mefenamic acid, and phenolphthalein. Flufenamic acid and phenolphthalein were much more potent inhibitors of ketone reduction than quercetin and menadione, implicating a greater role of AKRs than CBR in the reduction of boceprevir.
Carbonyl reduction of aldehydes, ketones, and quinones to their corresponding hydroxyl derivatives plays an important role in the Phase I metabolism of many endogenous (biogenic aldehydes, steroids, prostaglandins, and reactive lipid oxidation products) and xenobiotics (drugs, carcinogens, and toxicants) compounds. Carbonylreducing enzymes are grouped into two large protein superfamilies: the AKRs and the short-chain dehydrogenases/reductases. Human AKR family differs from the rodent families (Barski et al., 2008) .
AKRs are soluble NADPH oxidoreductases that primarily reduce aldehydes and ketones to primary and secondary alcohols, respectively. They play central roles in the metabolism of drugs, carcinogens, and reactive aldehydes. AKRs are Phase I drug-metabolizing enzymes for a variety of carbonyl-containing drugs and are implicated in cancer che- (Jin and Penning, 2007) . To date, 13 AKR proteins have been identified in humans. These include AKR1A1, AKR1B1 and AKR1B10, AKR1C1, AKR1C2, AKR1C3 and AKR1C4 (HSDs), AKR1D1, AKR6A3, AKR6A5, AKR6A9, AKR7A2, and AKR7A3 (Barski et al., 2008) . AKR1C isoforms are inhibited by NSAIDs and may cause drug-drug interactions.
Kinetic parameters showed that in vitro intrinsic clearance of M28 and M31 (V max /K m ratio 2.2 and 2.8, respectively) was similar in human liver cytosol. Incubation of SCH 534128 and SCH 534129, two diastereoisomers, with human liver cytosol showed that M28 was generated from SCH 534128 and M31 from SCH 534129. Hence, each isomer (SCH 534128 and SCH 534129) produced a single but different carbonyl-reduced metabolites (Mϩ2 product) with human cytosol.
Screening of [ 14 C]boceprevir (20 M) with recombinant human AKR1C2, AKR1C3, and AKR1C4 (enzymes expressed in HEK293 cell lines) in the presence of NADPH showed that AKR1C2 and AKR1C3 were involved in the formation of Mϩ2 metabolites. AKR1C3 preferentially metabolizes SCH 534128, the active isomer, and AKR1C2 preferentially metabolizes SCH 534129, the inactive isomer. No metabolites were detected with AKR1C4. It should be noted that involvement of AKR1C1 could not be assessed, because the clone was not available. Kinetic parameters for M28 formation with recombinant AKR1C2 and AKR1C3 showed that intrinsic clearance was higher with of AKR1C3 than AKR1C2 (Table 5) . Hence, AKR1C3 pathway may have preference over AKR1C2 for the formation of M28.
Inhibition studies were conducted in human liver cytosol with a series of AKR inhibitors including NSAIDs and benzodiazepines, which have been reported to be substrates and inhibitors of AKRs (Usami et al., 2002; Desmond et al., 2003; Bauman et al., 2005) . Our results showed that diazepam inhibited recombinant AKR1C2-and AKR1C3-mediated formation of M28 by 91 and 55%, respectively. These findings are consistent with previous reports that diazepam inhibited recombinant AKR1C2 and AKR1C3 with IC 50 values of 2.4 and 84 M, respectively (Usami et al., 2002) . Therefore, diazepam (low IC 50 and 91% inhibition) is a potent inhibitor of AKR1C2. Gobec et al. (2005) reported that NSAIDs like ibuprofen and flufenamic acid are inhibitors of AKR1C3. In addition, Higaki et al. (2003) reported diazepam, flufenamic acid, and phenolphthalein as inhibitors of AKR1C1-AKR1C4. Likewise, the present study also showed the inhibitory potential of NSAIDs on the formation of M28 from boceprevir via the AKR pathway. In vitro screening of various inhibitors suggests that diflunisal is the most potent inhibitor of AKR than all the others that have been tested, so far. Although diflunisal was a potent inhibitor of AKR-mediated formation of M28, CYP3A4-mediated oxidative metabolites were unaltered, suggesting that diflunisal is not an inhibitor of CYP3A4. Recent reports showed that the AKR family of enzymes is involved in the metabolism of several drugs such as HIV integrase inhibitor S-1360 (Rosemond et al., 2004; Shimizu et al., 2007) , kinesin spindle protein inhibitor (Li et al., 2010) , the opiate antagonists naltrexone and naloxone, a serotonin (5-HT 3 ) receptor antagonist (dolaserton) (Breyer-Pfaff and Nill, 2004) , the novel anticancer drug oracin (Wsol et al., 2007) , the anticancer drug daunorubicin, antihypertensive drug befunolol, the diuretic drug ethacrynic acid, and loxoprofen (NSAID) (Wsol et al., 2007; Barski et al., 2008) .
In conclusion, the results of this study demonstrated that CYP3A4 and CYP3A5 are capable of producing a large number of oxidative metabolites from boceprevir. However, the formation of M28 and M31, known to be major circulating plasma metabolites in humans, is most likely mediated by AKRs (AKR1C2 and AKR1C3). Because the biotransformation and clearance of boceprevir involves two different enzymatic pathways, namely, oxidation via CYP3A4/3A5 and ketoreduction via AKR, boceprevir is less likely to be victim of drug interaction with concomitantly administered drugs that are CYP3A4 inhibitors.
